HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 11, Pages 2763
Publisher
MDPI AG
Online
2021-06-02
DOI
10.3390/cancers13112763
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression
- (2020) Srinivasa P. Pothula et al. PANCREATOLOGY
- Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
- (2020) Zhihong Xu et al. BRITISH JOURNAL OF CANCER
- An Orthotopic Resectional Mouse Model of Pancreatic Cancer
- (2020) Tony C. Y. Pang et al. Jove-Journal of Visualized Experiments
- Comprehensive Integration of Single-Cell Data
- (2019) Tim Stuart et al. CELL
- The reactome pathway knowledgebase
- (2019) Bijay Jassal et al. NUCLEIC ACIDS RESEARCH
- Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer
- (2018) Ayse Ceren Mutgan et al. Molecular Cancer
- PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools
- (2018) Huaiyu Mi et al. NUCLEIC ACIDS RESEARCH
- STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
- (2018) Damian Szklarczyk et al. NUCLEIC ACIDS RESEARCH
- Derivation and Validation of the Potential Core Genes in Pancreatic Cancer for Tumor-Stroma Crosstalk
- (2018) Ran Xue et al. Biomed Research International
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Reversed graph embedding resolves complex single-cell trajectories
- (2017) Xiaojie Qiu et al. NATURE METHODS
- Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer
- (2017) Srinivasa P. Pothula et al. Oncotarget
- Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma
- (2016) Katherine E. Poruk et al. ANNALS OF SURGERY
- Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer
- (2016) Srinivasa P Pothula et al. BRITISH JOURNAL OF CANCER
- Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability
- (2016) D. R. Pattabiraman et al. SCIENCE
- Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia
- (2016) Toshiki Hirakawa et al. PLoS One
- Multi-Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining
- (2016) Daniel L Adams et al. Scientific Reports
- A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
- (2015) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Conditionally immortalized human pancreatic stellate cell lines demonstrate enhanced proliferation and migration in response to IGF-I
- (2015) Ann H. Rosendahl et al. EXPERIMENTAL CELL RESEARCH
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy
- (2015) Katherine M. Bever et al. HPB
- The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma
- (2015) Lai Mun Wang et al. Oncotarget
- Receptor for Hyaluronic Acid-Mediated Motility is Associated with Poor Survival in Pancreatic Ductal Adenocarcinoma
- (2015) Xiao-Bo Cheng et al. Journal of Cancer
- Comparison of the transcriptional landscapes between human and mouse tissues
- (2014) Shin Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells
- (2014) David T. Ting et al. Cell Reports
- Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
- (2012) Tobias M Gorges et al. BMC CANCER
- Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
- (2011) Matias E. Valsecchi et al. CANCER
- Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses
- (2011) M. N. Cabili et al. GENES & DEVELOPMENT
- Role of Pancreatic Stellate Cells in Pancreatic Cancer Metastasis
- (2010) Zhihong Xu et al. AMERICAN JOURNAL OF PATHOLOGY
- Malignant cells facilitate lung metastasis by bringing their own soil
- (2010) D. G. Duda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells
- (2008) A. Vonlaufen et al. CANCER RESEARCH
- Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
- (2008) R. F. Hwang et al. CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started